公开(公告)号：US20180228898A1

公开(公告)日：2018-08-16

申请号：US15939008

申请日：2018-03-28

Applicant: Ramscor, Inc.

Inventor： Vernon G. Wong ,  Louis L. Wood

IPC: A61K47/14 ,  A61K31/355 ,  A61K31/573 ,  A61K9/00 ,  A61K31/496 ,  A61K38/13 ,  A61K47/06

CPC classification number: A61K47/14 ,  A61K9/0019 ,  A61K9/0024 ,  A61K9/0048 ,  A61K9/0051 ,  A61K31/355 ,  A61K31/496 ,  A61K31/573 ,  A61K38/13 ,  A61K47/06

Abstract: This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states.

公开(公告)号：US20180221409A1

公开(公告)日：2018-08-09

申请号：US15914746

申请日：2018-03-07

Applicant: The Board of Trustees of the Leland Stanford Junior University

Inventor： Samuel Strober ,  Robert Lowsky

IPC: A61K35/12 ,  A61N5/10 ,  A61K39/395 ,  A61K35/22 ,  A61K35/17 ,  A61K35/28

CPC classification number: A61K35/12 ,  A61K31/365 ,  A61K31/436 ,  A61K31/573 ,  A61K35/14 ,  A61K35/17 ,  A61K35/22 ,  A61K35/28 ,  A61K38/13 ,  A61K38/193 ,  A61K39/001 ,  A61K39/395 ,  A61K39/39541 ,  A61K41/00 ,  A61K45/06 ,  A61K2035/122 ,  A61K2035/124 ,  A61K2039/515 ,  A61K2039/54 ,  A61K2039/57 ,  A61N5/10 ,  A61K2300/00

Abstract: Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.

公开(公告)号：US20180207271A1

公开(公告)日：2018-07-26

申请号：US15744254

申请日：2016-07-13

Applicant: CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV) ,  BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Michel GILLIET ,  Jeremy DI DOMIZIO ,  Stephan MELLER

IPC: A61K39/395 ,  A61P17/06

CPC classification number: A61K39/39566 ,  A61K31/194 ,  A61K31/505 ,  A61K38/13 ,  A61K2039/505 ,  A61K2300/00 ,  A61P17/06 ,  C07K16/244 ,  C07K2317/24 ,  C07K2317/76 ,  Y02A50/414

Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with interleukin 26 (IL-26), including inflammatory diseases, such as psoriasis and/or bacterial infections.

公开(公告)号：US20180186836A1

公开(公告)日：2018-07-05

申请号：US15740747

申请日：2016-06-30

Applicant: Cypralis Limited

Inventor： Michael Peel ,  Andrew Scribner ,  Koichi Watashi ,  Satomi Shimura

IPC: C07K7/64 ,  A61P31/20 ,  A61K38/13

CPC classification number: C07K7/645 ,  A61K38/00 ,  A61K38/13 ,  A61P31/20 ,  C07K7/64

Abstract: The invention relates to cyclic compounds of general formula (I): wherein R1, R2 and R3 are as defined in the specification, and their use as pharmaceuticals.

公开(公告)号：US10010577B2

公开(公告)日：2018-07-03

申请号：US15094400

申请日：2016-04-08

Applicant: Claresa Levetan

Inventor： Claresa Levetan

IPC: A61K38/00 ,  A61K38/17 ,  C07K7/08 ,  A61K38/10 ,  A61K38/13 ,  A61K47/48 ,  A61K45/06 ,  C07K14/47 ,  A61K38/21

CPC classification number: A61K38/1709 ,  A61K38/10 ,  A61K38/13 ,  A61K38/1732 ,  A61K38/212 ,  A61K39/395 ,  A61K45/06 ,  A61K47/60 ,  C07K7/08 ,  C07K14/474 ,  A61K2300/00

Abstract: Embodiments of the present invention provide for novel therapies, pharmaceutical compositions and methods for insulin independence utilizing a new optimized hamster Reg3 gamma peptide, which is new to the art and has not previously been considered for development in the 30 year history since its discovery. Methods, pharmaceutical compositions and therapies novel to the prior art are utilized in this invention to render patients with recent onset and existing type 1 diabetes insulin independent by an optimized hamster Reg3 gamma peptide and an immune tolerance agent for type 1 patients to become insulin independent and used alone without an immune tolerance agent for type 2 diabetes. While not wishing to be bound by theory, optimized Reg3 gamma peptides increases beta cell generation by its demonstrated properties shown within of transforming ductal pancreatic cells into new islets.

公开(公告)号：US20180171389A1

公开(公告)日：2018-06-21

申请号：US15736983

申请日：2016-06-16

Applicant: Murdoch Childrens Research Institute ,  St. Vincent's Hospital Melbourne

Inventor： Michael Albert Kamm ,  Carl Dunn Kirkwood ,  Peter-Philip De Cruz ,  Josef Wagner ,  Emily Kate Wright ,  Michael Tadao Ouye ,  Shu Mei Teo

IPC: C12Q1/689 ,  C12Q1/686

CPC classification number: C12Q1/689 ,  A61K38/13 ,  A61K45/06 ,  C12Q1/686 ,  C12Q1/6883 ,  C12Q2600/118

Abstract: The invention relates to the treatment of inflammatory bowel disease characterised by chronic inflammation. In particular, the invention relates to methods of predicting, treating or preventing post-operative recurrence of Crohn's disease.

公开(公告)号：US09993548B2

公开(公告)日：2018-06-12

申请号：US14161660

申请日：2014-01-22

Applicant: Selecta Biosciences, Inc.

Inventor： Roberto A. Maldonado

IPC: A61K47/48 ,  A61K39/00 ,  C07K16/18 ,  A61K9/51 ,  A61K9/58 ,  A61K47/00 ,  A61K9/14 ,  A61K39/385 ,  A61K39/35 ,  G01N33/50 ,  G01N33/569 ,  B82Y5/00 ,  A61K39/36 ,  A61K9/127 ,  A61K38/38 ,  A61K31/192 ,  A61K38/13 ,  A61K38/18 ,  A61K47/50 ,  A61K47/52 ,  A61K47/54 ,  A61K47/59 ,  A61K47/64 ,  A61K47/69 ,  B82Y40/00

CPC classification number: A61K39/385 ,  A61K9/127 ,  A61K9/14 ,  A61K9/51 ,  A61K9/5115 ,  A61K9/5146 ,  A61K9/5153 ,  A61K31/192 ,  A61K38/13 ,  A61K38/1816 ,  A61K38/38 ,  A61K39/00 ,  A61K39/0008 ,  A61K39/001 ,  A61K39/35 ,  A61K39/36 ,  A61K47/50 ,  A61K47/52 ,  A61K47/544 ,  A61K47/593 ,  A61K47/643 ,  A61K47/69 ,  A61K47/6923 ,  A61K47/6929 ,  A61K47/6937 ,  A61K2039/5154 ,  A61K2039/55511 ,  A61K2039/55555 ,  A61K2039/577 ,  B82Y5/00 ,  B82Y40/00 ,  G01N33/505 ,  G01N33/56972 ,  G01N2333/7051 ,  G01N2333/70514 ,  G01N2333/70517 ,  Y02A50/401 ,  Y02A50/41 ,  A61K2300/00

Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising B cell and/or MHC Class II-restricted epitopes and immunosuppressants in order to generate tolerogenic immune responses, such as the generation of antigen-specific regulatory B cells.

公开(公告)号：US09993439B2

公开(公告)日：2018-06-12

申请号：US14410521

申请日：2013-06-20

Applicant: UNIVERSITY OF WATERLOO

Inventor： Frank X. Gu ,  Lyndon William James Jones ,  Shengyan (Sandy) Liu

IPC: A61K9/51 ,  A61K47/26 ,  A61K38/13 ,  A61K9/00 ,  A61K45/06 ,  A61K31/131 ,  A61K31/69 ,  A61K31/78 ,  A61K49/00 ,  A61K47/54 ,  A61K47/69

CPC classification number: A61K9/5161 ,  A61K9/006 ,  A61K9/5123 ,  A61K9/5153 ,  A61K9/5192 ,  A61K31/131 ,  A61K31/69 ,  A61K31/78 ,  A61K38/13 ,  A61K45/06 ,  A61K47/26 ,  A61K47/54 ,  A61K47/549 ,  A61K47/6935 ,  A61K47/6937 ,  A61K47/6939 ,  A61K49/0002 ,  Y02A50/409 ,  Y10T428/2982

Abstract: The present disclosure relates generally to a mucoadhesive nanoparticle delivery system. The nanoparticles are formed from amphiphilic macromolecules conjugated to a mucosal targeting moiety in such a manner that the surface of the nanoparticle is coated with the targeting moiety. The surface density of the targeting moiety can be tuned for adjustable targeting of the nanoparticles to a mucosal site without substantially compromising the stability of the particles. The particles were found to have high loading efficiency and sustained release properties at the mucosal site. The present disclosure also relates to polymers and macromolecules useful in the preparation of the mucoadhesive nanoparticles, as well as compositions, methods, commercial packages, kits and uses related thereto.

公开(公告)号：US09987356B2

公开(公告)日：2018-06-05

申请号：US14004552

申请日：2012-03-12

Applicant: Keith A. Reimann ,  Rijian Wang ,  Christian P. Larsen

Inventor： Keith A. Reimann ,  Rijian Wang ,  Christian P. Larsen

IPC: A61K39/395 ,  C07K16/18 ,  A61K45/06 ,  A61K31/436 ,  C07K16/28 ,  A61K38/13 ,  A61K39/00

CPC classification number: A61K39/3955 ,  A61K31/436 ,  A61K38/13 ,  A61K39/39541 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/18 ,  C07K16/2866 ,  C07K16/2875 ,  C07K16/2878 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/76 ,  Y02A50/386 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/414 ,  Y02A50/423 ,  A61K2300/00

Abstract: The present invention relates to antibodies specific for a particular epitope on CD40 and antibodies that bind CD40 and have particular functional characteristics. The present invention also relates to fragments of these antibodies, uses of the antibodies for reduction or treatment of transplant rejection and graft-versus-host disease, and methods for making the antibodies.

公开(公告)号：US09981041B2

公开(公告)日：2018-05-29

申请号：US15244617

申请日：2016-08-23

Applicant: Ira Jason Salzman

Inventor： Ira Jason Salzman

IPC: A61K47/38 ,  A61K31/7036 ,  A61M11/00 ,  A61F9/00 ,  A61K38/13 ,  A61K31/4725 ,  A61D7/00 ,  A61K31/56 ,  A61K9/12 ,  A61K47/06 ,  A61K9/00

CPC classification number: A61K47/38 ,  A61D7/00 ,  A61K9/0048 ,  A61K9/12 ,  A61K31/4725 ,  A61K31/56 ,  A61K31/7036 ,  A61K38/13

Abstract: An ophthalmic composition for administration as a spray to the eye is provided. The ophthalmic composition comprises a lubricant comprising hydroxypropyl methylcellulose (HPMC), mineral oil, and sterile water. The ophthalmic composition is also configured as a delivery vehicle for administration of ophthalmic pharmaceuticals to the eye. A method of treating keratoconjunctivitis sicca by administering the ophthalmic composition is also provided.